A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of candesartan on the carbohydrates metabolism, of non diabetic, non hypertensive subjects with dysglycemia and abdominal obesity. 'ARAMIA'

Trial Profile

A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of candesartan on the carbohydrates metabolism, of non diabetic, non hypertensive subjects with dysglycemia and abdominal obesity. 'ARAMIA'

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Glucose intolerance; Obesity
  • Focus Pharmacodynamics
  • Acronyms ARAMIA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Nov 2010 Planned end date changed from Dec 2009 to Feb 2011 as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top